New Tools to Screen and Diagnose Cervical Cancer in Women
Compares a rapid HPV test with an optical imaging device for cervical changes.
Plain-language title generated from the registry record
Registry title: Rice Technologies for Cervical Cancer Screening and Diagnosis
Key facts
- Where
- Maputo, MozambiqueSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 49 years old?
Source: NCT05372484, who can take part
Where in Mozambique
- José Macamo General Hospital and Health CenterMaputo, MozambiqueTaking people
- Maputo Central HospitalMaputo, MozambiqueTaking people
- Mavalane Hospital and Health CenterMaputo, MozambiqueTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- M.D. Anderson Cancer Center
- Trial code
- NCT05372484
- Record updated
- 10 August 2026
- Original description
The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology.Read full original descriptionShow less
Assessment of New Technologies for the Screening and Diagnosis of Cervical Cancer in Mozambique, A Study to be Conducted in Maputo Central Hospital, Mavalane and Jose Macamo General Hospitals and Mavalane Health Center
The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology.
Inclusion: 25 - 49 year old women; Women with a positive cervical cancer screening test (abnormal cytology, positive VIA and/or positive HPV test); Women with intact cervix; Women who are not pregnant and with a negative pregnancy test (within 14 days from the date of enrollment) ) and not currently breastfeeding; Willing and capable of providing informed consent.
Exclusion: Women under 25 or over 49 years old; Women who have undergone a total hysterectomy (with removal of the cervix); Women who are pregnant or breastfeeding.